The company tested its system in the diagnosis of liver disease.
BreathID Ltd. (TASE:BRTI), which was floated a month ago, announced today that it successfully completed a trial on 15 patients with Acute Liver Disease.
The trial, which was conducted at the Hadassah Medical Center assessed the patients using BreatheID's non-invasive device, which diagnoses diseases of the liver and other symptoms by analyzing the composition of the air exhaled from the patients' lungs. The results were then compared with those obtained from the existing procedures for monitoring these patients. It was found that BreathID's device produced similar results to those of the existing testing procedures, without having to wait a day or more for the results.
BreatheID's system is a diagnostic device so the company will be able to begin marketing it to for use in trials at leading medical centers, although its commercial success will depend on the completion of trials on a larger scale. BreathID has already successfully completed trials of its device on patients with Hepatitis C and Non Alcoholic Fatty Liver Disease.
Published by Globes [online], Israel business news - www.globes.co.il - on June 24, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007